Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20296680-iovance-biotherapeutics-highlights-business-achievements-pipeline-milestones-and-third] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q3 GAAP EPS of -$0.25 beats by $0.01.
* Revenue of $67.46M (+15.2% Y/Y) misses by $5.35M.
* Cash and cash equivalents, investments, and restricted cash totaled ~$307 million as of September 30, 2025. The current cash position, bolstered by expense reductions, is expected to fund operations into the second quarter of 2027.
* Full-year 2025 revenue guidance is reaffirmed within the range of $250 to $300 million in the first full calendar year of Amtagvi sales (VS. CONSENSUS OF $266.68M).

MORE ON IOVANCE BIOTHERAPEUTICS

* Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play [https://seekingalpha.com/article/4829013-iovance-stock-q3-earnings-may-smart-but-long-term-bull-thesis-remains-in-play]
* Iovance: Thin Margins, Dilution Threat Keep Risk Skewed [https://seekingalpha.com/article/4817182-iovance-thin-margins-dilution-threat-keep-risk-skewed]
* Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 [https://seekingalpha.com/article/4815812-iovance-biotherapeutics-tough-decisions-being-made-but-catalysts-in-h225]
* Iovance Biotherapeutics Q3 2025 Earnings Preview [https://seekingalpha.com/news/4515791-iovance-biotherapeutics-q3-2025-earnings-preview]
* Goldman's 48 potential M&A candidates [https://seekingalpha.com/news/4499689-goldmans-48-potential-ma-candidates]